Umbilical Cord Mesenchymal Stem Cell Transplantation for Decompensated Hepatitis B Cirrhosis

Asia Stem Cell Regenerative Pharmaceutical

Status

Enrolling

Conditions

Liver Cirrhosis

Treatments

Drug: UC-MSC infusion

Study type

Interventional

Funder types

Industry

Identifiers

NCT05106972

SCT20181032

Details and patient eligibility

About

This study aims to evaluate the safety and clinical efficacy of umbilical cord mesenchymal stem cell transplantation for decompensated hepatitis B cirrhosis.

Enrollment

30 estimated patients

Sex

All

Ages

20 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged between 20 and 60 (male or female)
Diagnosed chronic decompensated hepatitis B cirrhosis with a course of more than 5 years
Not suitable for liver transplantation or there is no donor liver source
No serious bleeding tendency or active bleeding
No hepatic encephalopathy
After strict medical conservative treatment for more than 6 months, there was no relief of symptoms or significant improvement of quality of life score
Subjects voluntarily participate in this study and sign informed consent

Exclusion criteria

Be less than 20 years old or more than 60 years old
Cirrhosis caused by other causes such as alcoholic hepatitis, hepatitis C virus and autoimmune hepatitis
Found liver malignant tumor or the family history of liver malignant tumor in the third generation of their direct relatives
Patients with hypersplenism who need splenectomy
History of tumors in other organs
PT prolongation is greater than 3 seconds
Use of human serum albumin within 3 weeks prior to clinical registration
Clinically significant upper gastrointestinal bleeding events occurred within 4 weeks before clinical registration
Spontaneous peritonitis
Active infection (viral or bacterial)
Pregnant or lactating women
The researcher considers it inappropriate to participate in this study